1-3 of 3
A. Douglas Laird, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Free
Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1344.
https://doi.org/10.1182/blood-2019-122097
Published: 2019
Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Free
Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4031.
https://doi.org/10.1182/blood-2018-99-110552
Published: 2018
Journal Articles

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Free
Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, MD, Wendy Stock, MD, Michaela Liedtke, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Jane Liang White, ScD, Tao Wang, PhD, A. Douglas Laird, PhD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2557.
https://doi.org/10.1182/blood.V130.Suppl_1.2557.2557
Published: 2017